[Skip to Content]
[Skip to Content Landing]
JAMA Clinical Guidelines Synopsis
July 18, 2019

Management of Patients With Acute Ischemic Stroke

Author Affiliations
  • 1University of Chicago, Chicago, Illinois
JAMA. 2019;322(8):777-778. doi:10.1001/jama.2019.10436

Acute stroke is a time-critical clinical condition and a leading cause of long-term disability. There has been rapid progress in the treatment of AIS recently, with high-quality clinical evidence from randomized trials providing support for endovascular interventions. Much of this evidence has come since the publication of previous AIS management guidelines by the AHA in 2013.

These guidelines were developed by a writing group appointed by the AHA Stroke Council’s Scientific Statements Oversight Committee, relying on systematic review of identified clinical questions by an independent evidence review committee (Table).1 The recommendations were approved by the full writing group and reviewed prior to release by 4 external reviewers and by the Stroke Council Leadership Committee. Members of the writing group were required to disclose conflicts of interest and to recuse themselves from discussions or votes on related topics. The AHA/ASA, the funding source for the guideline, is partly supported by contributions from pharmaceutical companies and medical device manufacturers.